Abstract
Objective Inflammatory bowel disease (IBD) is characterized by dysregulated intestinal immune responses and constitutes a major clinical challenge in need of new treatment modalities to improve patient care. Store-operated Ca2+ entry (SOCE) is the predominant Ca2+ influx pathway in T cells and other immune cells, regulating many of their functional properties. It is currently unknown whether the pharmacologic blockade of SOCE represents a suitable drug-target for IBD treatment.
Design Using mass and flow cytometry the effects of SOCE inhibition on lamina propria (LP) immune cells of patients with ulcerative colitis (UC) and Crohn’s disease (CD) were investigated. Primary organoid cultures served to study the impact of SOCE inhibition on the function, differentiation and survival of intestinal epithelial cells (IEC). T cell transfer models of colitis were applied to examine how the genetic or pharmacologic ablation of SOCE affects the clinical course of IBD in mice.
Results We observed that the LP of IBD patients is characterized by an enrichment of innate lymphoid cells (ILC), CD4+ and CD8+ effector- as well as T regulatory cells producing IL-17 and TNFα. The pharmacologic inhibition of SOCE attenuated the production of pathogenic cytokines including IL-2, IL-4, IL-6, IL-17, TNFα and IFNγ by human colonic T cells and ILC, reduced the production of IL-6 by B cells and the production of IFNγ by myeloid cells, without affecting the viability, differentiation and function of primary IEC. T cell-specific genetic deletion of the SOCE signaling components Orai1, Stim1 or Stim2 revealed that the magnitude of SOCE correlates with the function of T cells and intestinal inflammation in mice. Moreover, the pharmacologic inhibition of SOCE alleviated the clinical course of colitic mice.
Conclusion Our data suggest that SOCE inhibition may serve as a new pharmacologic strategy for treating IBD.
Competing Interest Statement
S.F. is a scientific cofounder of CalciMedica. K.S. is a co-founder and CSO of CalciMedica. B.S. has served as consultant for Abbvie, Arena, BMS, Boehringer, Celgene, Falk, Galapagos, Janssen, Lilly, Pfizer, Prometheus and Takeda and received speaker fees from Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Pfizer, Takeda [payments were made to the institution]. None of the other authors declare competing interests.
Funding Statement
This work was funded by the German Research Foundation (We 5303/3-1 to C.W., Si 749/10-1 to B.S., SFB-TRR 241 B01 to B.S. and C.W., SFB TRR167 B05 to CB) and NIH grants AI097302, AI130143 and AI137004 (to S.F.), a Senior Research Award by the Crohn's and Colitis Foundation of America (to S.F.) and an Irma T. Hirschl career scientist award (to S.F.) M.B. and J.F.Z. received financial support from the Einstein Foundation Berlin. C.W. received funding by the Clinician Scientist Program of the Berlin Institute of Health and by the Fritz-Thyssen-Foundation (10.19.2.028MN).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All experiments involving human material were approved by the institutional review board of the Charite- Universitaetsmedizin Berlin and conducted accordingly. All animal experiments were performed in accordance to institutional guidelines for animal welfare approved by the Institutional Animal Care and Use Committee at New York University School of Medicine.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All mass and flow cytometric data sets are available from the corresponding authors on reasonable request that does not include confidential patient information.